MCT4 Promotes Hepatocellular Carcinoma Progression by Upregulating TRAPPC5 Gene
Zheyu Niu,Faji Yang,Hongguang Li,Jianlu Wang,Qingqiang Ni,Chaoqun Ma,Huaqiang Zhu,Hong Chang,Xu Zhou,Jun Lu,Hengjun Gao
DOI: https://doi.org/10.2147/JHC.S352948
2022-04-09
Journal of Hepatocellular Carcinoma
Abstract:Zheyu Niu, &ast Faji Yang, &ast Hongguang Li, &ast Jianlu Wang, Qingqiang Ni, Chaoqun Ma, Huaqiang Zhu, Hong Chang, Xu Zhou, Jun Lu, Hengjun Gao Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong Provincial Hospital Affiliated to Shandong University, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Lu; Hengjun Gao, Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong Provincial Hospital affiliated to Shandong University, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China, Email ; Purpose: Monocarboxylate transporter 4 (MCT4) is an important component of cancer cell glycolytic metabolism. It has been confirmed that MCT4 is highly expressed in hepatocellular carcinoma (HCC) cells and tissues and is significantly associated with poor prognosis of HCC patients. However, research on its downstream molecules that affect HCC is still insufficient. The aim of current research was to investigate the MCT downstream molecule and its role of in HCC development. Patients and Methods: After MCT4 expression was knocked down by RNA interference, RNA sequencing and quantitative real-time PCR were used to screen for differentially expressed genes in an HCC cell line (HCCLM3). Immunohistochemistry in HCC tissue microarray was carried out to evaluate the Trafficking Protein Particle Complex Subunit 5 (TRAPPC5) expression. Cell proliferation, migration, and invasion were evaluated by CCK-8 assay, colony formation assay, transwell and wound-healing test, respectively. Xenograft experiment was employed to investigate the function of TRAPPC5 on tumor growth in vivo. Related signaling pathway proteins were evaluated by Western blot. Results: TRAPPC5 expression was significantly downregulated after knocking down of MCT4 in HCCLM3. TRAPPC5 was highly expressed in HCC tissues, and it could enhance the proliferation, migration, invasion and epithelial–mesenchymal transition (EMT) process of HCC cells. In vivo experiment showed that TRAPPC5 could promote HCC tumorigenesis. Conclusion: In the process of MCT4 affecting the progression of HCC, TRAPPC5 is one of the most important related molecules. TRAPPC5 suppression could significantly reduce HCC cell proliferation, migration and invasion and could serve as a therapeutic target in HCC. Keywords: MCT4, hepatocellular carcinoma, TRAPPC5, RNA sequencing, tissue microarrays Hepatocellular carcinoma (HCC) accounts for approximately 80% of primary liver malignancies, and is considered the sixth most common cancer and the third leading cause of cancer deaths worldwide. 1,2 Most cases are treated with surgical resection, percutaneous ablation and transarterial chemoembolization (TACE) depends on tumor burden, location and comorbidities. Although there have been significant advances in targeted drugs (antiangiogenic tyrosine kinase inhibitors) and immunotherapy (anti-PD1 agents) in recent years, the 5-year average survival rate of HCC patients is still less than 20%. 3,4 In addition to conventional clinicopathological factors such as lymph node metastasis, PNI, pathological grade, and staging, many molecules such as AFP, HSP90 and GPC-3 have been widely studied and applied as prognostic biomarkers involved in tumorigenesis and development, 5,6 more studies is needed to help providing effective treatment targets and prognostic markers. Monocarboxylate transporter 4 (MCT4) is an effective lactic acid transporter and an important component of cancer cell glycolytic metabolism. And lactate efflux results in an acidic tumor microenvironment, which contributes to tumor invasion, metastasis, immunosurveillance avoidance, and therapeutic resistance. 7 Overexpression of MCT4 has been reported associated with poor survival of head and neck cancer, 8 Adrenocortical carcinoma, 9 lung cancer, 10 Glioblastoma, 11 breast cancer 12 and colorectal cancer. 13 In our previous study, it has been confirmed that MCT4 is highly expressed in HCC cells and tissues, promotes the proliferation, invasion and metastasis of tumor cells, and is significantly associated with poor prognosis of HCC patients. MCT4 might be a therapeutic target for HCC. 14 However, research on its downstream molecules that affect HCC is still insufficient. In this study, MCT4 expression in HCC cells was knocked down by RNA interference, Trafficking Protein Particle Complex Subunit 5 (TRAPPC5) gene was screened out by high-throughput sequencin -Abstract Truncated-
oncology